Dr. Analoui is Managing Director at Pickwick Capital Partners and Adjunct Professor at Brown University and UConn. Previously he was the Executive Director of Venture Development and Technology Incubation Program (TIP) at UConn. Prior to that, he was Head of Healthcare and Life Sciences at Livingston Securities (New York, NY) with investment focus in private and public companies in biotech, medtech and healthcare services. He was the Senior Director at Pfizer Global Research and Development. Dr. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies. While at Pfizer, he was the Site Head for Global Clinical Technology in Groton and New London, a division focusing on emerging technologies for development and validation of biomarkers and diagnostics for drug development. Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research, Associate Professor of Radiology at Indiana University, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc. He has received his PhD from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY. Dr. Analoui teaches BIOL 2528 Innovation and Commercialization in Medical Devices, Diagnostics, and Wearables.

Dr. Taiese Bingham-Hickman is the Executive Director of The Leadership Alliance at Brown University. The Leadership Alliance is a consortium of 41 academic and industry partners that provide research, mentoring, and networking experiences to undergraduate students, graduate students and research professionals. She previously served as the Assistant Director of Biomedical Informatics Research and Operations at Brown University Associate Director for Biomedical Informatics at Brown University where she supported the operational functions of the Brown Center for Biomedical Informatics (BCBI) and the NIGMS-funded Advance-CTR Biomedical Informatics Core. Before joining Brown University, Dr. Bingham-Hickman worked in the private industry at Beacon Health Options as the Vice President of Data Analytics where she oversaw Beacon’s Analytics Innovation Center that provided thought leadership and analytic capabilities to ensure optimal behavioral health solutions for regional and specialty health plans; employers and labor organizations; and federal, state and local governments. Dr. Bingham-Hickman is a member of the Industry Council for the Masters in Data Analytics Program at Merrimack College which brings together experts in data science and business analytics to provide strategic guidance and support for the program. Dr. Bingham-Hickman is also the founder and CEO of New England Equity Collective, a non-profit dedicated to promoting opportunity in equity and access to homeownership and affordable housing to underserved communities. Dr. Bingham-Hickman holds a unique and multifaceted role, pivotal in shaping the organization’s direction, ethos, and strategies in alignment with its mission to promote equity and access to homeownership. Dr. Bingham-Hickman earned both M.S. and Ph.D. degrees from New York University School of Medicine and completed her M.B.A at Northeastern University. She received a B.S. from the University of Maryland Eastern Shore. 

Barrett Bready is the Founder and CEO of Nabsys, a genomics company located in Providence that has developed a new way of looking at DNA called High Definition Mapping. Dr. Bready has raised approximately $150 million for the development and commercialization of HD-Mapping, which uses multiplexed solid-state nanodetectors to electronically interrogate very long DNA molecules. Dr. Bready is an adjunct professor at Brown University where he lectures on the rapidly evolving business of biotechnology. He serves as a commissioner of the I-195 Redevelopment District Commission, a major land redevelopment initiative in downtown Providence, RI with a focus on life sciences and other high-technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year, and in 2018, a career achievement award from the Warren Alpert Medical School of Brown University. Dr. Bready received an MD and an ScB. in physics from Brown University, both as part of Brown’s Program in Liberal Medical Education (PLME). Dr. Bready teaches BIOL 0080 Biotechnology Management.

Dr. Christian, is an experienced scientist interested in drug discovery biology. He received his ScB in Neuroscience and the prestigious James T. Mcllwain Award for Excellence in Neuroscience at Brown University. He later received his Master's and PhD degrees in Molecular Pharmacology and Physiology from Brown University. Donald has a record of accomplishments in mentoring, teaching, and coaching younger scientists during his tenure as lead scientist for high-content imaging, at Casma Therapeutics. Over the years, he has designed new course content for various courses at Brown and served as a guest lecturer in courses like Physiological Pharmacology, Molecular Pharmacology, Development of Vaccines to Infectious Diseases, and Assays in Drug Discovery. He is currently the lead lecturer of the Pharmacokinetics (PK) course, which he has revamped to include how industry considerations in drug discovery influence the PK property of a drug. Dr. Christian teaches BIOL 2135 Pharmacokinetics and Drug Design.

Dr. Fisher is the Assistant Dean of the College for Pre-Professional Advising. She received her BS degree in Biology and Environmental Health from the Indiana University of Pennsylvania and her Masters and PhD in Aquatic Physiology from Wake Forest University. Her early research focused on the physiology of aquatic organisms including unionid freshwater mussels and the marine copepod tigriopus californicus. She then moved to the area of Biology Education Research where she examined the development and impact of course-based undergraduate research experiences on students’ science identity, motivation and attitude. In her time as an Associate Professor of Biology at the University of Northern Colorado she taught a variety of courses including Introductory Biology, Physiological Ecology, Marine Biology and Foundations of Clinical Research. She also developed and directed the masters in Biomedical Science program at the university. She has won numerous awards, including the Donald Bletz Award for Outstanding Teaching, the Natural and Health Sciences Excellence in Advising and Excellence in Leadership Awards as Center for Human Enrichment Outstanding Faculty and Staff award. Dr. Fisher will begin teaching in the Fall of 2024.

Daniel is Co-Chairman of Intellectual Property Group at Adler Pollock & Sheehan. P.C. He has extensive experience in developing and executing honest and straightforward strategies for clients' intellectual property portfolios with a sharply honed focus on furthering their business objectives. As a registered patent attorney with the United States Patent and Trademark Office, Daniel has a passionate focus on assisting a wide range of clients from early stage technology companies to Fortune 500 companies located throughout the United States and Canada with their intellectual property law issues. More specifically, Daniel advocates and counsels clients in intellectual property areas such as patents, trademarks, copyrights, trade secrets, unfair competition, and domain names. Daniel's range of technology areas is vast including medical devices, software, biofuels, nanotechnology, material science, eyewear, coatings, vaccines, chemicals, consumer packaging, biotechnology, and green technologies. 

Daniel advises on all aspects of intellectual property protection including prosecution, procurement, federal litigation, proceedings before the Patent and Trial Appeal Board (PTAB) (i.e. reexaminations and interferences), Trademark Trial and Appeals Board (TTAB) (i.e. oppositions, cancellations, appeals), reexamination, interference, Uniform Domain-Name Dispute Resolution Policy (UDRP) proceedings, licensing from technology transfer offices and others, and auctioning of IP. Furthermore, he is a registered patent attorney with the U.S. Patent Office and admitted to the federal district courts in Rhode Island and Massachusetts. He received his BA in business administration from UMass Amherst and his JD from Temple University’s James E. Beasley School of Law. Daniel teaches BIOL 2089 The Importance of Intellectual Property in Biotechnology.

Dr. Huang is a life science industry veteran specializing in advancing innovative and transformative technologies with early-stage startups. He is currently interim Chief Operating Officer at Saga Diagnostics, leading the set-up of its US site and hiring of the initial US team. He was previously Chief Scientific Officer at Mercy BioAnalytics, which is developing extracellular vesicle-based diagnostics for the early detection of cancer. Prior to that, Dr. Huang held senior management and advisory positions at GelMEDIX, Gloucester Marine Genomics Institute, Klotho Therapeutics, Glympse Bio and Acusphere. Dr. Huang serves on the Scientific Advisory Board at 3Helix and is also an adjunct faculty member at Brown University. He completed his PhD in Medical Science at Brown University. MS in Biomedical Engineering from Rutgers University, and ScB in Biomedical Engineering from Brown University. Dr. Huang teaches BIOL 2020 Biotech, Science, and Industry.

Dr. Jong brings over 15 years of management consulting experience in the pharma/biotech field to provide real world context to management strategies in the classroom. Yong currently serves as a Principal in the Corporate & Portfolio Strategy team at IQVIA where he develops strategic and portfolio management approaches tailored to client decision-making, investment culture and key company objectives. Before transitioning to the commercial side, Yong was employee #1 at Spherics, a venture backed biotech startup from Brown, developing technologies in gene delivery/biomaterials and published in leading scientific journals such as Nature. Yong received his MBA from The Tuck School of Business at Dartmouth College and his PhD and BS from Brown University. Dr. Jong teaches BIOL 2018 Management Strategies in Biotechnology.

Karen F. Mahoney, Esq. is the Worldwide Vice President, Regulatory Affairs at DePuy Synthes, Johnson & Johnson. Karen leads the DePuy Synthes Regulatory organization with responsibility for driving regulatory strategy and execution for the Orthopedics business worldwide. She has extensive knowledge of the DePuy Synthes business and is a proven leader who has worked at Johnson & Johnson in the DePuy Synthes companies for 25 years, and within the medical device industry for 27 years. Throughout her career, she has had the opportunity to work on all classifications of products in the Spine, Neurovascular, Sports Medicine, Trauma/CMF/Biomaterials, Joints, CMW, Powertools and Digital business units.  Karen has held global roles in Regulatory Affairs, NPD Quality and Compliance. 

Karen is currently on the Board of the Orthopedic Surgical Manufacturers Association (OSMA), is a member of the Advamed Orthopedic Working Group, and a member of the Regulatory Affairs Professionals Society (RAPS).  Karen previously served as a Medical Device Committee Board Member of the Food and Drug Law Institute (FDLI). 

Karen holds a B.S. in Biology from Fairfield University and received her Juris Doctor degree from Roger Williams University, School of Law. She is licensed to practice law in the states of Massachusetts and Rhode Island. Karen will be teaching BIOL 2078, Regulatory Affairs in Pharma, Med Device and Digital Health.

Dr. Simon has worked in drug discovery for more than 20 years, most recently focusing her efforts on the preclinical development of RNA-targeting therapeutics for the treatment of CNS disorders at start-up companies such as PepGen and Aliada. There, her work focused on characterizing the uptake, mechanism of action, and biodistribution of current and next-generation compounds. Dr. Simon previously led the in vitro biology efforts at Atalanta Therapeutics, where her team was responsible for compound screening, target validation, lead candidate selection, ex vivo tissue analysis for compound efficacy and DMPK analysis. Before that, she spent a very diverse 18 years in rare disease research at Sanofi-Genzyme. During that time, her work primarily focused on the biochemistry of pulmonary fibrosis, solid tumor and hematologic oncology, hemoglobinopathies, and cystic fibrosis. Kailene received her B.S. in Biology from Providence College, her M.S. in Biology from Tufts University and her Ph.D. in Biochemistry from the University of Massachusetts Medical School. Dr. Simon will be teaching BIOL 2024, Gene and RNA Therapeutic Development.

Dr. Toth is the Director of the Multi-Disciplinary Laboratories in the Biology Undergraduate Education Office in the Division of Biology and Medicine. He received his BS degree in Biology from the University of Toledo and his PhD in Microbiology and Immunology from the University of Virginia. He was a post-doctoral researcher in the Department of Microbiology and Immunology at the University of California, San Francisco. Prior to Brown, Chuck was an Associate Professor of Biology at Providence College, he taught courses in Cell Biology and Molecular Genetics (science writing course); Developmental Biology; Immunology, Research; General Biology; Human Biology; Advanced Topic Seminars on Public Health, Stem Cells, Drug Discovery, Bioinformatics and HIV; Liberal Arts Honors Colloquia on Personalized Medicine, HIV, the Human Brain, Public Health- A Global Perspective; and the Neuroscience Capstone. His research focused on utilizing human induced pluripotent cells to develop disease models. He was the long-time department chair of Biology, served as co-director of the Neuroscience Concentration, and received the Joseph R. Accinno Faculty Teaching Award while at Providence College. He was a member of the IDeA Networks of Biomedical Research Excellence (INBRE) Steering Committee, a University of Rhode Island led NIH state-wide research grant. Dr. Toth teaches BIOL 1050/2050 Biology of the Eukaryotic Cell.